Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 13/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.60 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | FAP | Q12884 | 3/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770258 | 0.88 | PREP (0.57) | PREPDPP7CNR1CNR2FAP | |
| SCHEMBL771667 | 0.82 | PREP (0.55) | PREPFAPDPP8DPP9DPP4 | |
| SCHEMBL770007 | 0.78 | PREP (0.60) | PREPDPP7FAP | |
| SCHEMBL770966 | 0.77 | RAB9A (0.51) | PREPDPP7CNR1CNR2FAP | |
| SCHEMBL770599 | 0.75 | DRD3 (0.48) | — | |
| SCHEMBL770799 | 0.74 | DPP4 (0.60) | PREPDPP7FAPALDH1A1DPP4 | |
| SCHEMBL769774 | 0.74 | SLC6A4 (0.51) | ALDH1A1 | |
| SCHEMBL771034 | 0.74 | PREP (0.59) | PREPCNR1CNR2 | |
| SCHEMBL770920 | 0.71 | RAB9A (0.54) | ALDH1A1 | |
| SCHEMBL770967 | 0.71 | RAB9A (0.56) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | PREP 900/4885DPP7 1093/4885CNR1 1805/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | PREP 907/4885DPP7 1113/4885CNR1 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.